Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-04
2010-12-28
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100
Reexamination Certificate
active
07858330
ABSTRACT:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 6503510 (2003-01-01), Koishihara et al.
patent: 2003/0148408 (2003-08-01), Frantz et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2005/0226869 (2005-10-01), Chang et al.
patent: 2005/0266008 (2005-12-01), Graziano et al.
patent: 2008/0292632 (2008-11-01), Pastan et al.
patent: WO 9963088 (1999-12-01), None
patent: WO 01/38490 (2001-05-01), None
patent: WO 01/38490 (2001-05-01), None
patent: WO 0138490 (2001-05-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO03/089624 (2003-10-01), None
patent: WO03/097803 (2003-11-01), None
O'Connell et al. Am J Clin Pathol, 2004, 121:254-263.
Rawstron et al. Br J Haematology, 1997, 97:46-55.
Gussow et al. (1991, Methods in Enzymology 203:99-121).
Blast Searches A1-A44.
Blast Searches B1-B18.
Blast Searches C1-C53.
Blast Searches D1-D35.
Blast Searches E1-E14.
Blast Searches F1-F28.
Blast Searches G1-G202.
Blast Searches H1-H107.
Blast Searches I1-I39.
Blast Searches J1-J19.
Blast Searches K1-K4.
Blast Searches L1-L23.
Blast Searches M1-M63.
Blast Searches N1-N35.
Boring et al., “Cancer Statistics, 1993”CA: A Cancer Journal for Clinicians43(1):7-26 (Jan.-Feb. 1993).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990)
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (Nov. 1990).
Ellis et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma”The Journal of Immunologypp. 925-937 (1995).
Hatzivassiliou et al., “IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy”Immunity14(3):277-289 (Mar. 2001).
Herrera et al., “Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins”Leukemia17(2):334-338 (Feb. 2003).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”Molecular&Cellular Biology8(3):1247-1252 (Mar. 1988).
Miller et al, “IRTAs: A new family of immunoglobulinlike receptors differentially expressed in B cells”Blood99(8):2662-2669 (2002).
Szatrowski et al., “Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 93”Cancer97(6):1471-1480 (Mar. 15, 2003).
Tassone et al., “Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma ce”Blood104(12):3688-3696 (Dec. 1, 2004).
Tobinai kensai, “Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma”Int J Clin Oncol. 8(4):212-223 (Aug. 2003).
Tur MK et al., “Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells”Cancer Research63(23):8414-8419 (Dec. 1, 2003).
von Mehren et al., “Monoclonal antibody therapy for cancer”Annu Rev Med. 54:343-369 (2003).
Conway, E.J., et al., “Phenotyping Studies of Clonotypic B Lymphocytes from Patients with Multiple Myeloma by Flow Cytometry”, Arch Pathol Labe Med, vol. 133, pp. 1594-1599, (2009).
Office Action mailed Dec. 27, 2007—U.S. Appl. No. 11/315,529.
Office Action mailed Dec. 10, 2008—U.S. Appl. No. 11/315,529.
Final Office Action mailed Jun. 9, 2009—U.S. Appl. No. 11/315,529.
Boyd, The Basic science of oncology, p. 379, (1992).
Euhus, et al., Surgery, Gynecology and Obstetrics, vol. 175, Abstract, (1992).
Gao, et al., Aizheng, vol. 21, Abstract, (2002).
Green, et al., Immunological Reviews, vol. 193, pp. 70-81, (2003).
Gura, Science, 278: 1041-1042, (1997).
Gussow, et al., Methods in Enzymology, 203: 99-121, (1991).
Harlow and Lane, Antibodies: A laboratory manual, Cold Spring Harbor Laboratory, pp. 141-142, (1988).
Kaiser, Science, 313: 1370, (2006).
Morrison, et al., “Complement activation and Fc receptor binding by IgG”, Protein engineering of antibody molecules for prophylactic and therapeutic applications, pp. 101-113, (1993).
Rihova, Advanced drug delivery reviews, vol. 29, pp. 273-289, (1998).
Rudikoff, et al., PNAS, vol. 79, pp. 1979-1983, (1982).
Schlom, “Monoclonal antibodies: They're more and less than you think”, Molecular foundations of oncology, pp. 95-134, (1991).
Chang Wesley
de Sauvage Frederic J.
Eaton Dan L.
Ebens, Jr. Allen J.
Frantz Gretchen D.
Arnold & Porter LLP
Bernhardt Jeffery P.
Genentech Inc.
Halvorson Mark
Yeung Bonny
LandOfFree
Compositions and methods for the treatment of tumor of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of tumor of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of tumor of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201242